The development of monoclonal antibodies—human immune proteins that can provide rapid, passive protection against some infectious diseases—is progressing quickly and holds great promise for expanding ...
As hospitals face the strain of a third surge of COVID-19, effective treatments for COVID-19 are sorely needed. SARS-CoV-2 monoclonal antibodies (mAbs) are among the latest investigational COVID-19 ...
WASHINGTON — Despite a scarce supply, a substantial amount of COVID-19 monoclonal antibody (mAb) treatment courses remain unused, says a new rapid expert consultation from the National Academies of ...
LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore the ...
As COVID deaths continue to spike across the U.S.—primarily among unvaccinated populations—newly developed treatments for the disease are again receiving attention. Monoclonal antibody (mAb) therapies ...
CHARLESTON, W.Va. — West Virginia’s congressional delegates are requesting additional Regeneron monoclonal antibody doses as hospitals and other health care facilities remain under tremendous stress ...
There is an increasing number of high-concentration mAbs among approved therapeutics, with 76% of US Food and Drug Administration (FDA)-approved mAbs having high concentration formulations, says ...
The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results